Before taking phentermine

Do not take phentermine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take phentermine before the MAO inhibitor has cleared from your body.

Taking phentermine together with other diet medications such as fenfluramine (Phen-Fen) or dexfenfluramine (Redux) can cause a rare fatal lung disorder called pulmonary hypertension. Do not take phentermine with any other diet medications without your doctor's advice.

What is phentermine?

 

Phentermine is a stimulant that is similar to an amphetamine. It is an appetite suppressant that affects the central nervous system.

Phentermine is used togther with diet, exercise and behavioral modification to treat obesity (excessively overweight) in people with risk factors such as high blood pressure, high cholesterol, or diabetes.

Phentermine may also be used for other purposes not listed in this medication guide.

With obesity on the rise, a variety of oral treatments are now obtainable in the market. But ‘how to opt for an effective obesity management?’ is the question that prevails in our mind.

Mr. Robert Parker, a senior marketing executive at Online Adipex comments, “in the midst of the a range of medications presented in the market, Adipex diet drug has emerged as one of the preferred diet supplement to an entire weight loss schedule facilitate weight loss. It is a short-term treatment which is employed by many obese to fetch effective weight loss”.

Adipex: HOW SUPPLIED
Available in tablets and capsules containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg phentermine base). Each blue and white, oblong, scored tablet is debossed with “ADIPEX-P” and “9”-“9”.

The #3 capsule has an opaque white body and an opaque bright blue cap. Each capsule is imprinted with “ADIPEX-P” - “37.5” on the cap and two stripes on the body using dark blue ink.
Tablets are packaged in bottles of 30 (NDC 57844-009-56); 100 (NDC 57844-009-01); and 1000 (NDC 57844-009-10).

Adipex: DOSAGE AND ADMINISTRATION

Exogenous Obesity: Dosage should be individualized to obtain an adequate response with the lowest effective dose. The usual adult dose is one capsule or tablet (37.5 mg) daily, administered before breakfast or 1-2 hours after breakfast. For tablets, the dosage may be adjusted to the patient’s need. For some patients 1/2 tablet (18.75 mg) daily may be adequate, while in some cases it may be desirable to give 1/2 tablet (18.75 mg) two times a day.

Late evening medication should be avoided because of the possibility of resulting insomnia.

Phentermine is not recommended for use in patients sixteen (16) years of age and under.

ADVERSE REACTIONS
Cardiovascular: Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure.

Central Nervous System: Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache; rarely psychotic episodes at recommended doses.

DOSAGE AND ADMINISTRATION

For the treatment of painful conditions Tramadol  50 mg to 100 mg can be administered as needed for relief every four to six hours, not to exceed 400 mg per day. For moderate pain Tramadol 50 mg may be adequate as the initial dose, and for more severe pain Tramadol 100 mg is usually more effective as the initial dose.

DRUG ABUSE AND DEPENDENCE

Although tramadol can produce drug dependence of the µ-opioid type (like codeine or dextropropoxyphene) and potentially may be abused, there has been little evidence of abuse in foreign clinical experience. In clinical trials, tramadol produced effects similar to an opioid, and at supratherapeutic doses was recognized as an opioid in subjective/behavioral studies. Tolerance development has been reported to be relatively mild and withdrawal when present, is not considered to be as severe as that produced by other opioids. Part of tramadol's activity and some extension of the duration of µ-opioid activity. Delayed µ-opioid activity is believed to reduce a drug's abuse liability.

An assay for tramadol is not included in routine urine screens for drugs of abuse.

ADVERSE REACTIONS:

Tramadol was administered to 550 patients during the double-blind or open-label extension periods in U.S. studies of chronic nonmalignant pain. Of these patients, 375 were 65 years old or older. TABLE 1 reports the cumulative incidence rate of adverse reactions by 7, 30 and 90 days for the most frequent reactions (5% or more by 7 days).

DRUG INTERACTION

Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.

Concomitant administration of Tramadol  with carbamazepine causes a significant increase in tramadol metabolism, presumably through metabolic induction by carbamazepine. Patients receiving chronic carbamazepine doses of up to 800 mg daily may require up to twice the recommended dose of Tramadol.